PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Buprenorphine initiation in the ER found safe and effective for individuals with opioid use disorder who use fentanyl

With historically high overdose death rates in U.S., multi-site NIH study reinforces importance of continued, uninterrupted access to addiction medication

2023-03-30
(Press-News.org)                   

Buprenorphine initiation in the ER found safe and effective for individuals with opioid use disorder who use fentanyl

With historically high overdose death rates in U.S., multi-site NIH study reinforces importance of continued, uninterrupted access to addiction medication

 

Results from a multi-site clinical trial supported by the National Institutes of Health showed that less than 1% of people with opioid use disorder whose drug use includes fentanyl experienced withdrawal when starting buprenorphine in the emergency department. The findings, which appeared today in JAMA Network Open, are strong evidence that buprenorphine, a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder, can be safely started in the emergency department without triggering withdrawal, even for people who use stronger opioids. Clinician concern over this type of withdrawal can be a barrier to using this treatment.

Withdrawal induced by medications to treat opioid use disorder – called precipitated withdrawal – is a debilitating experience marked by rapid onset of symptoms such as aches, nausea and vomiting, diarrhea, and abdominal cramps that can occur within two hours after the first dose of buprenorphine. Although instances of buprenorphine-precipitated withdrawal have only been reported in relatively small case studies and anecdotal evidence, some clinicians and patients worry that the risk of experiencing precipitated withdrawal from buprenorphine might be increased among people who use fentanyl. This has led some clinicians to prescribe buprenorphine at lower doses, especially for people using extremely potent illicit opioids such as fentanyl. Because initiating low-dose buprenorphine following initial cessation of illicit opioids can be less effective in relieving these symptoms, individuals may be more likely to resume use of illicit opioids. 

The study, supported by the National Institute on Drug Abuse (NIDA) through NIH’s Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, should help assuage concerns over precipitated withdrawal following buprenorphine treatment in the emergency department.

“We are in an overdose crisis, and we need to deploy every tool we have to help address it,” said Nora D. Volkow, M.D., director of NIDA. “The emergency department is a crucial care setting for people with substance use disorders. This study provides further evidence that all emergency department physicians can and should be using buprenorphine to help individuals take the first steps into treatment and toward recovery.”

There has been an urgent need to better understand how the prevalence of fentanyl in the drug supply affects the process of addiction treatment for people with opioid use disorder. The study addressed this question prospectively by analyzing data from 1,200 individuals at 28 U.S. emergency departments participating in an ongoing clinical trial. The trial is comparing the relative impact of a weekly extended-release buprenorphine injection at a dose of 24 milligrams versus daily administration of 8 to 16 mg buprenorphine as a tablet or film.

The trial recruited adult patients with untreated moderate to severe opioid use disorder, opioid-positive and methadone-negative urine tests, and a Clinical Opiate Withdrawal Scale score greater than or equal to 4. In this study, precipitated withdrawal was defined as when a patient demonstrated marked escalation by five points or more on the Clinical Opiate Withdrawal Scale within two hours of starting buprenorphine. Researchers found that despite high fentanyl use prevalence – about 76% – among 1,200 people with opioid use disorder, precipitated withdrawal occurred in nine out of the total 1,200 people, or 0.76%, and only 0.98% of those who had used fentanyl. The rate of precipitated withdrawal was similar to that reported in people using heroin or prescription opioids without fentanyl.

“Clinicians should encourage patients with opioid use disorder to take buprenorphine if they need it,” said lead author Gail D’Onofrio, M.D., professor of emergency medicine at Yale University, New Haven, Connecticut. “We know that less than 23% of people with opioid use disorder are getting treated for it, and we only have a few medications for opioid use disorder that have been found to be very effective for opioid withdrawal to date. If we take away one of these, we’re going to have an even bigger gap between need and treatment. We hope that both clinicians and patients understand that buprenorphine is a safe and effective option.”

These findings build upon existing evidence that administering buprenorphine in emergency departments helps people begin addiction treatment and that higher-dose buprenorphine (more than the standard upper limit of 16 mg) is safe and well tolerated in people with opioid use disorder experiencing withdrawal symptoms. They also bolster support for expanding access to buprenorphine. Recent legislation removed barriers to access, including the elimination of the X-Waiver in December 2022, and policy efforts have been initiated that maintain COVID-19 era-initiated flexibilities related to prescribing buprenorphine via telehealth evaluations.

“The emergency department is an important touchpoint for providing life-saving medication and resources for people at risk for overdose,” said Rebecca G. Baker, Ph.D., director of the NIH HEAL Initiative. “We need to meet people where they are amid an increasingly deadly overdose crisis.” 

This work was supported by NIDA’s Clinical Trials Network (UG1DA015831-18S7), a nationwide consortium aimed at testing drug use interventions and delivering evidence-based therapies to diverse patient populations. Additional support was provided by the NIH HEAL Initiative.

---------------------------------------------

For more information on substance and mental health treatment programs in your area, call the free and confidential National Helpline 1-800-662-HELP (4357) or visit www.FindTreatment.gov. 

Reference: G. D’Onofrio, et al. Incidence of Precipitated Withdrawal during a Multi-site Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2023.6108 (2023).

###
 

About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

About the NIH HEAL Initiative: The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov.

About substance use disorders: Substance use disorders are chronic, treatable conditions from which people can recover. In 2021, over 46 million people in the United States had at least one substance use disorder. Substance use disorders are defined in part by continued use of substances despite negative consequences. They are also relapsing conditions, in which periods of abstinence (not using substances) can be followed by a return to use. Stigma can make individuals with substance use disorders less likely to seek treatment. Using preferred language can help accurately report on substance use and addiction. View NIDA’s online guide.


NIH…Turning Discovery Into Health®

END



ELSE PRESS RELEASES FROM THIS DATE:

Severe hepatitis outbreak linked to common childhood viruses

2023-03-30
A new UC San Francisco-led study brings scientists closer to understanding the causes of a mysterious rash of cases of acute severe hepatitis that began appearing in otherwise healthy children after COVID-19 lockdowns eased in the United States and 34 other countries in the spring of 2022. Pediatric hepatitis is rare, and doctors were alarmed when they started seeing outbreaks of severe unexplained hepatitis. There have been about 1,000 cases to date; 50 of these children needed liver transplants and at least 22 have died. In the study, publishing on March 30 in Nature, researchers linked the disease to co-infections from multiple common viruses, in particular a strain of ...

New nanoparticles can perform gene-editing in the lungs

2023-03-30
CAMBRIDGE, MA -- Engineers at MIT and the University of Massachusetts Medical School have designed a new type of nanoparticle that can be administered to the lungs, where it can deliver messenger RNA encoding useful proteins. With further development, these particles could offer an inhalable treatment for cystic fibrosis and other diseases of the lung, the researchers say. “This is the first demonstration of highly efficient delivery of RNA to the lungs in mice. We are hopeful that it can be used to treat or repair ...

Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer

2023-03-30
About The Study: In this study of 690 patients with early-stage breast cancer, racial disparities in response to neoadjuvant chemotherapy were associated with disparities in survival and varied across different breast cancer subtypes. This study highlights the potential benefits of better understanding the biology of primary and residual tumors.  Authors: Olufunmilayo I. Olopade, M.B.B.S., and Dezheng Huo, M.D., Ph.D., of the University of Chicago, are the corresponding authors.  To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/  (doi:10.1001/jamanetworkopen.2023.3329) Editor’s ...

Racial, ethnic, education differences in age of smoking initiation among young adults

2023-03-30
About The Study: Declines in smoking prevalence and increases in the age of smoking initiation occurred more slowly for young adults with less formal education, widening existing education disparities between 2002 and 2019. Black young adults had lower smoking prevalence and older age of smoking initiation than white young adults. However, declines in smoking prevalence and increases in the age of smoking initiation occurred more slowly for this group.  Authors: Alyssa F. Harlow, Ph.D., of the University of Southern California ...

Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease

Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
2023-03-30
HOUSTON ― A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center. The study, published today in Nature Medicine, represents the first-in-human trial of concurrent IT and IV nivolumab (anti-PD-1) in melanoma patients ...

Surprise finding shows that neutrophils can be key antitumor weapons

Surprise finding shows that neutrophils can be key antitumor weapons
2023-03-30
White blood cells called neutrophils have an unappreciated role in eradicating solid tumors, according to a surprise discovery from a team led by Weill Cornell Medicine scientists. In the study, published March 30 in Cell, the researchers investigated how a T cell-based immunotherapy was able to destroy melanoma tumors even though many of the tumor cells lacked the markers or “antigens” targeted by the T cells. They found that the T cells, in attacking the tumors, activated a swarm of neutrophils—which in turn killed the tumor cells that the T cells couldn’t ...

Monitoring chronic disease burden: EHRs can help meet a serious public health challenge

2023-03-30
INDIANAPOLIS – The pandemic has highlighted the importance of increasing the flow of information on infectious diseases from electronic health records (EHRs) to public health agencies. Less attention has been paid to the value of EHR data for chronic disease surveillance. At the HIMSS (Healthcare Information and Management Systems Society) Global Health Conference & Exhibition (HIMSS23), Brian Dixon, PhD, MPA, of Regenstrief Institute and Indiana University Richard M. Fairbanks School of Public Health and Lorna Thorpe, PhD, MPH, of NYU Grossman School of Medicine, will ...

Exploiting dark autoionizing states for enhancing the extreme ultraviolet laser power

Exploiting dark autoionizing states for enhancing the extreme ultraviolet laser power
2023-03-30
Exploiting dark autoionizing states for enhancing the extreme ultraviolet laser power A research team unravels a new optical phenomenon involving dark autoionizing states, enhancing the power of an extreme-ultraviolet laser. An international research team led by Professors Tsuneyuki Ozaki and François Légaré at the Institut national de la recherche scientifique (INRS), has developed a unique method to enhance the power of a laser source emitting extreme ultraviolet light pulses. The underlying mechanism of the newly observed phenomenon involves the ...

Iridium-based catalysts look set to boost efficiency of green hydrogen production

Iridium-based catalysts look set to boost efficiency of green hydrogen production
2023-03-30
Hydrogen production powered by wind and solar energy is still too expensive if it is to play a role in the clean transition via energy storage and to help decarbonize hard-to-electrify sectors. Much effort in reducing its cost focuses on enhancing production efficiency by improving the performance of iridium-based catalysts that can speed up the oxygen-related part of the electrochemical reaction involved in splitting water into its component parts, hydrogen and oxygen. A new review of the state of the field discusses its recent progress and challenges and identifies research gaps that need to be filled before such ...

A promising outlook: CAR T cells improve patient quality of life

2023-03-30
(WASHINGTON, March 30, 2023) – Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, yet relatively few studies have investigated the impact of the therapy on longitudinal patient quality of life – an aspect of care that often suffers from receiving traditional intensive cancer medications, such as chemotherapy. A new study published in Blood Advances demonstrates that some effective cancer treatments do improve quality of life, revealing that patients with blood cancers experienced ...

LAST 30 PRESS RELEASES:

Scientists unlock secrets behind flowering of the king of fruits

Texas A&M researchers illuminate the mysteries of icy ocean worlds

Prosthetic material could help reduce infections from intravenous catheters

Can the heart heal itself? New study says it can

Microscopic discovery in cancer cells could have a big impact

Rice researchers take ‘significant leap forward’ with quantum simulation of molecular electron transfer

Breakthrough new material brings affordable, sustainable future within grasp

How everyday activities inside your home can generate energy

Inequality weakens local governance and public satisfaction, study finds

Uncovering key molecular factors behind malaria’s deadliest strain

UC Davis researchers help decode the cause of aggressive breast cancer in women of color

Researchers discovered replication hubs for human norovirus

SNU researchers develop the world’s most sensitive flexible strain sensor

Tiny, wireless antennas use light to monitor cellular communication

Neutrality has played a pivotal, but under-examined, role in international relations, new research shows

Study reveals right whales live 130 years — or more

Researchers reveal how human eyelashes promote water drainage

Pollinators most vulnerable to rising global temperatures are flies, study shows

DFG to fund eight new research units

Modern AI systems have achieved Turing's vision, but not exactly how he hoped

Quantum walk computing unlocks new potential in quantum science and technology

Construction materials and household items are a part of a long-term carbon sink called the “technosphere”

First demonstration of quantum teleportation over busy Internet cables

Disparities and gaps in breast cancer screening for women ages 40 to 49

US tobacco 21 policies and potential mortality reductions by state

AI-driven approach reveals hidden hazards of chemical mixtures in rivers

Older age linked to increased complications after breast reconstruction

ESA and NASA satellites deliver first joint picture of Greenland Ice Sheet melting

Early detection model for pancreatic necrosis improves patient outcomes

Poor vascular health accelerates brain ageing

[Press-News.org] Buprenorphine initiation in the ER found safe and effective for individuals with opioid use disorder who use fentanyl
With historically high overdose death rates in U.S., multi-site NIH study reinforces importance of continued, uninterrupted access to addiction medication